Search
01/05/2022
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
Garcia-Fortes, M, Hernandez-Boluda, JC, Alvarez-Larran, A, Raya, JM, Angona, A, Estrada, N, Fox, L, Cuevas, B, Garcia-Hernandez, MC, Gomez-Casares, MT, Ferrer-Marin, F, Saavedra, S, Cervantes, F, Garcia-Delgado, R. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 2022; 14(9)DOI:10.3390/cancers14092331. PMID:35565461. IF:5.200(Q2/3D).
01/05/2022
Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers
Arranz, MJ, Salazar, J, Bote, V, Artigas-Baleri, A, Serra-LLovich, A, Trivino, E, Roige, J, Lombardia, C, Cancino, M, Hernandez, M, Cendros, M, Duran-Tauleria, E, Maraver, N, Hervas, A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. Pharmaceutics. 2022; 14(5)DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5.400(Q1/2D).
01/05/2022
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Reinoso-Segura, M, Caballero-Velazquez, T, Herrera, P, Patriarca, F, Fanin, R, Bruno, B, Einsele, H, Nahi, H, Granell, M, Lopez-Corral, L, Reguera, JL, Garcia-Cadenas, I, Gahrton, G, Perez-Simon, JA. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation And Cellular Therapy. 2022; 28(5)DOI:10.1016/j.jtct.2022.01.026. PMID:35131486. IF:3.200(Q2/5D).
25/04/2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Orgueira, AM, Perez, MSG, Arias, JD, Rosinol, L, Oriol, A, Teruel, AI, Lopez, JM, Palomera, L, Granell, M, Blanchard, MJ, de la Rubia, J, de la Guia, AL, Rios, R, Sureda, A, Hernandez, MT, Bengoechea, E, Calasanz, MJ, Gutierrez, N, Martin, ML, Blade, J, Lahuerta, JJ, San Miguel, J, Mateos, MV. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00647-z. PMID:35468898. IF:12.800(Q1/1D).
19/04/2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, C, Hernandez-Rivas, JA, Oriol, A, Rosinol, L, Blanchard, MJ, Bellon, JM, Garcia-Sanz, R, de la Rubia, J, de la Guia, AL, Jimenez-Ubieto, A, Jarque, I, Inigo, B, Dourdil, V, de Arriba, F, Perez-Avila, CC, Gonzalez, Y, Hernandez, MT, Bargay, J, Granell, M, Rodriguez-Otero, P, Silvent, M, Cabrera, C, Rios, R, Alegre, A, Gironella, M, Gonzalez, MS, Sureda, A, Sampol, A, Ocio, EM, Krsnik, I, Garcia, A, Garcia-Mateo, A, Soler, JA, Martin, J, Arguinano, JM, Mateos, MV, Blade, J, San-Miguel, JF, Lahuerta, JJ, Martinez-Lopez, J. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00652-2. PMID:35440057. IF:12.800(Q1/1D).
01/03/2022
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients
Ramos-Campoy, S, Puiggros, A, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Ortega, M, Blanco, ML, Collado, R, Salgado, R, Baumann, T, Gimeno, E, Moreno, C, Bosch, F, Calvo, X, Calasanz, MJ, Cuneo, A, Strefford, JC, Nguyen-Khac, F, Oscier, D, Haferlach, C, Schoumans, J, Espinet, B. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. HAEMATOLOGICA. 2022; 107(3)DOI:10.3324/haematol.2020.274456. PMID:33691382. IF:10.100(Q1/2D).